Transitional Cell Cancer of the Renal Pelvis and Ureter: Causes and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Upper tract urothelial carcinoma (UTUC) — historically termed transitional cell carcinoma (TCC) of the renal pelvis and ureter — is a malignancy arising from the urothelial lining of the collecting system above the urinary bladder. It accounts for approximately 5–10% of all renal tumors and 5–10% of all urothelial cancers. Renal pelvis tumors are twice as common as ureteral tumors. UTUC is predominantly a disease of older adults, with a mean age at diagnosis of 70–73 years and a male predominance (3:1). Unlike bladder cancer, where low-grade papillary tumors are common, the majority of UTUC cases (~70%) are high-grade at diagnosis and are associated with more aggressive behavior. Bilateral involvement occurs in approximately 2–4% of sporadic cases but is much more common (up to 25%) in Lynch syndrome-associated UTUC. Synchronous or metachronous bladder cancer occurs in approximately 20–50% of patients with UTUC, necessitating regular cystoscopic surveillance.

UTUC shares many risk factors with bladder urothelial carcinoma. Tobacco smoking is the strongest modifiable risk factor, increasing UTUC risk two- to four-fold through urinary carcinogen (aromatic amine) excretion. Aristolochic acid nephropathy — from ingestion of herbal remedies containing Aristolochia species, endemic in parts of Taiwan, China, and the Balkans — causes a distinctive UTUC with TP53 mutations and AT>TA transversions, and is responsible for epidemic UTUC in affected regions. Occupational exposure to aromatic amines (benzidine, beta-naphthylamine — textile dyes, rubber industry) substantially increases risk. Chronic analgesic abuse (phenacetin) was historically a major cause. Balkan endemic nephropathy is a geographic risk factor in Bulgaria, Romania, Bosnia, and Croatia. Lynch syndrome (hereditary nonpolyposis colorectal cancer, HNPCC — MSH2, MLH1, MSH6, PMS2 mutations) confers substantially elevated lifetime UTUC risk (~4–12%). Chronic urinary tract infections and calculi promote urothelial inflammation and field cancerization.

The most common presenting symptom of UTUC is painless gross hematuria (visible blood in the urine), which occurs in approximately 70–80% of cases and is similar in character to bladder cancer hematuria — typically total hematuria throughout the urinary stream. Microscopic hematuria on routine urinalysis is another common presentation, particularly in early-stage disease. Flank or loin pain — resulting from ureteral obstruction causing hydronephrosis or from clot passage — occurs in approximately 20–30% of cases. A palpable flank mass may rarely be detected in advanced renal pelvis tumors. Lower urinary tract symptoms — frequency, urgency, dysuria — may occur if the tumor extends to or involves the distal ureter near the bladder. Constitutional symptoms including weight loss, fatigue, and anorexia suggest advanced disease with distant metastasis. Up to 20% of UTUC is detected incidentally on cross-sectional imaging performed for other indications. Any episode of gross hematuria in an adult warrants complete upper and lower tract evaluation.

Evaluation follows the European Association of Urology (EAU) UTUC guideline framework. CT urography (CTU) — triple-phase CT with delayed excretory phase — is the primary imaging modality and detects filling defects, urothelial thickening, hydronephrosis, and extraureteral spread. MR urography is used for patients with contrast allergy or renal impairment. Urine cytology is performed but has limited sensitivity for low-grade UTUC; FISH (fluorescence in situ hybridization) or uCyte test may supplement cytology. Diagnostic ureteroscopy with direct visualization and cold-cup biopsy of suspected lesions establishes the diagnosis and permits grade assessment — critical for surgical planning. Selective ureteral barbotage for cytology enhances sensitivity. Staging is based on TNM (8th edition): Ta/T1 (confined to mucosa/lamina propria), T2 (muscularis propria), T3 (renal parenchyma/peripelvic fat), T4 (adjacent organs), N (lymph node involvement), M (distant metastasis). Chest CT and bone scan complete staging in high-risk cases. Lynch syndrome testing (microsatellite instability, germline MMR gene testing) is recommended for UTUC diagnosed before age 60, bilateral disease, or family history.

Radical nephroureterectomy (RNU) with ipsilateral bladder cuff excision is the standard surgical treatment for high-grade, large, or muscle-invasive UTUC. The bladder cuff excision (complete removal of the distal ureter with the ureteral orifice) is mandatory to prevent ureteral stump recurrence. Laparoscopic or robotic-assisted RNU provides equivalent oncological outcomes to open surgery with lower morbidity and is now the preferred approach at experienced centers. Neoadjuvant cisplatin-based chemotherapy (MVAC — methotrexate, vinblastine, doxorubicin, cisplatin — or GC — gemcitabine/cisplatin) is recommended before RNU for high-risk UTUC (high-grade biopsy, muscle invasion on imaging) as per EAU guidelines and the POUT trial results; adjuvant cisplatin-based chemotherapy after RNU is also supported. Kidney-sparing (endoscopic ablative) treatment — ureteroscopic laser ablation or percutaneous approaches — is considered for low-grade, low-risk, or solitary kidney disease. Post-operative single instillation of intravesical mitomycin C immediately after RNU reduces bladder recurrence rate (ODMIT-C trial). Immune checkpoint inhibitors (pembrolizumab) are approved for platinum-pretreated advanced/metastatic UTUC.

The prognosis of upper tract urothelial carcinoma (UTUC) is strongly stage-dependent, reflecting the aggressive behavior of the majority of cases — approximately 70% of which are high-grade at diagnosis. Non-invasive (pTa) and lamina propria-invasive (pT1) tumors have a relatively favorable 5-year overall survival of approximately 70–85% after radical nephroureterectomy. Muscle-invasive disease (pT2) carries a 5-year survival of approximately 50–65%, while peripelvic fat or renal parenchymal invasion (pT3) reduces survival to 30–45%. Locally advanced (pT4) or node-positive disease has a 5-year survival below 20%, and distant metastases reduce median survival to 12–18 months. Adjuvant cisplatin-based chemotherapy (gemcitabine-cisplatin) significantly improves disease-free survival in high-risk patients (pT2–T4 and/or N+), as demonstrated by the POUT randomized trial (HR 0.45). Neoadjuvant cisplatin-based chemotherapy is preferred when feasible, as post-operative renal function is often compromised by nephrectomy. Bladder urothelial carcinoma develops synchronously or metachronously in 20–50% of patients, requiring lifelong cystoscopic surveillance; a single intravesical mitomycin C instillation after nephroureterectomy reduces bladder recurrence by approximately 50%. Contralateral upper tract recurrence occurs in 2–6% of patients at 5 years. Lynch syndrome-associated UTUC affects younger patients and carries higher risk of bilateral upper tract involvement requiring heightened bilateral surveillance. Pembrolizumab is approved for platinum-pretreated metastatic disease, offering durable responses in selected patients.

Tobacco cessation is the most impactful preventive measure — smoking cessation substantially reduces long-term UTUC risk. Avoidance of aristolochic acid-containing herbal remedies is critical in at-risk populations. Occupational exposure reduction through use of protective equipment in chemical, rubber, and dye industries is important. Patients with Lynch syndrome should undergo regular upper tract surveillance (CT urography annually) and lower tract cystoscopy. Post-treatment surveillance after RNU includes cystoscopy every 3 months for the first year (to detect bladder recurrence), then every 6 months up to 5 years, then annually — combined with CT urography annually to detect contralateral UTUC and distant metastasis. Urinary cytology at each visit complements cystoscopy. Patients treated with kidney-sparing endoscopic procedures for low-risk UTUC require more intensive endoscopic surveillance given the higher local recurrence rate.

Any adult experiencing painless visible (gross) hematuria requires prompt urological evaluation — this should never be attributed to urinary tract infection without upper and lower tract investigation in adults over age 35. Microscopic hematuria (≥3 RBCs/HPF on two of three urine samples) in adults over 35 also warrants urological evaluation. Flank pain with hematuria — particularly in a patient without a history of urinary stones — requires urgent CT urography to exclude obstructing upper tract tumor. Patients with prior bladder urothelial carcinoma who develop upper tract symptoms (flank pain, new hematuria) need evaluation for synchronous or metachronous UTUC. Known Lynch syndrome patients should have established surveillance protocols and any new urological symptoms should prompt urgent assessment. Patients presenting with unexplained constitutional symptoms (weight loss, fatigue, anorexia) and hematuria need expedited evaluation to exclude advanced urothelial malignancy.